Skip to main content
Top
Published in: Rheumatology International 8/2021

01-08-2021 | Systemic Lupus Erythematosus | Observational Research

Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population

Authors: Courtney Hardy, Dafna D. Gladman, Jiandong Su, Nathalie Rozenbojm, Murray B. Urowitz

Published in: Rheumatology International | Issue 8/2021

Login to get access

Abstract

To estimate the level of medication adherence and barriers to adherence among systemic lupus erythematosus (SLE) patients. Patients taking antimalarials, immunosuppressives, and/or steroids to treat SLE were included. Adherence was measured using the Medication Adherence Self Report Inventory (MASRI) and adherence rates < 80% were considered nonadherent while rates ≥ 80% sufficiently adherent. Pill counts were conducted in a proportion of participants. Barriers to adherence were identified using the Identification of Medication Adherence Barriers Questionnaire 30 (IMAB-Q 30). Associations between adherence and patient demographics and disease-specific characteristics were explored. A total of 94 patients were studied and 28 pill counts conducted. 10 patients were classified as nonadherent and 84 patients as sufficiently adherent. 46% of patients were taking steroids, 77.7% antimalarials, and 55.3% immunosuppressives. 88% of patients were taking ≥ 1 medication for non-SLE conditions. The mean medication adherence rate for the SLE patients was 90.7%. Important barriers to adherence reported by nonadherent patients were: concern about harmful side effects (50%), being easily distracted (50%), life getting in the way (50%), being unsure or disagreeing that their condition will worsen without medications (50%), and having personal reasons for not taking medications (50%). Non-adherent patients reported significantly more barriers than sufficiently adherent patients (p < 0.001). The adherence rate in our population was higher than expected, reaching 90%. Barriers to medication adherence were identified and should be addressed on a population and individualized basis to improve patient outcomes.
Literature
3.
go back to reference Koneru S, Kocharla L, Higgins GC, Ware A, Passo MH, Farhey YD, Mongey AB, Graham TB, Houk JL, Brunner HI (2008) Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 14:195–201CrossRef Koneru S, Kocharla L, Higgins GC, Ware A, Passo MH, Farhey YD, Mongey AB, Graham TB, Houk JL, Brunner HI (2008) Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 14:195–201CrossRef
4.
go back to reference Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, Katz P (2009) Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 61:240–246CrossRef Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA, Katz P (2009) Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 61:240–246CrossRef
5.
go back to reference Rojas-Serrano J, Cardiel MH (2000) Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 9:601–606CrossRef Rojas-Serrano J, Cardiel MH (2000) Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 9:601–606CrossRef
6.
go back to reference Feldman CH, Yazdany J, Guan H, Solomon DH, Costenbader KH (2015) Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res 67:1712–1721CrossRef Feldman CH, Yazdany J, Guan H, Solomon DH, Costenbader KH (2015) Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res 67:1712–1721CrossRef
7.
go back to reference Chehab G, Sauer GM, Richter JG, Brinks R, Willers R, Fischer-Betz R, Winkler-Rohlfing B, Schneider M (2018) Medical adherence in patients with systemic lupus erythematosus in Germany: predictors and reasons for non-adherence—a cross-sectional analysis of the LuLa-cohort. Lupus 27:1652–1660CrossRef Chehab G, Sauer GM, Richter JG, Brinks R, Willers R, Fischer-Betz R, Winkler-Rohlfing B, Schneider M (2018) Medical adherence in patients with systemic lupus erythematosus in Germany: predictors and reasons for non-adherence—a cross-sectional analysis of the LuLa-cohort. Lupus 27:1652–1660CrossRef
8.
go back to reference Mehat P, Atiquzzaman M, Esdaile JM, AviÑa-Zubieta A, De Vera MA (2017) Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res 69:1706–1713CrossRef Mehat P, Atiquzzaman M, Esdaile JM, AviÑa-Zubieta A, De Vera MA (2017) Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res 69:1706–1713CrossRef
9.
go back to reference Oliveira-Santos M, Verani JF, Klumb EM, Albuquerque EM (2011) Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus 20:320–329CrossRef Oliveira-Santos M, Verani JF, Klumb EM, Albuquerque EM (2011) Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus 20:320–329CrossRef
10.
go back to reference Abdul-Sattar AB, Abou El Magd SA (2015) Determinants of medication non-adherence in Egyptian patients with systemic lupus erythematosus: Sharkia Governorate. Rheumatol Int 35:1045–1051CrossRef Abdul-Sattar AB, Abou El Magd SA (2015) Determinants of medication non-adherence in Egyptian patients with systemic lupus erythematosus: Sharkia Governorate. Rheumatol Int 35:1045–1051CrossRef
11.
go back to reference Garcia-Gonzalez A, Richardson M, Popa-Lisseanu MG, Cox V, Kallen MA, Janssen N, Ng B, Marcus DM, Reveille JD, Suarez-Almazor ME (2008) Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 27:883–889CrossRef Garcia-Gonzalez A, Richardson M, Popa-Lisseanu MG, Cox V, Kallen MA, Janssen N, Ng B, Marcus DM, Reveille JD, Suarez-Almazor ME (2008) Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 27:883–889CrossRef
12.
go back to reference Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ (2019) Understanding nonadherence with hydroxychloroquine therapy in systemic lupus erythematosus. J Rheumatol 46:1309–1315CrossRef Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ (2019) Understanding nonadherence with hydroxychloroquine therapy in systemic lupus erythematosus. J Rheumatol 46:1309–1315CrossRef
13.
go back to reference Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, Passo MH, Houk JL, Higgins GC, Brunner HI (2007) Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Care Res 57:1000–1006CrossRef Koneru S, Shishov M, Ware A, Farhey Y, Mongey AB, Graham TB, Passo MH, Houk JL, Higgins GC, Brunner HI (2007) Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Care Res 57:1000–1006CrossRef
15.
go back to reference Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271CrossRef Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271CrossRef
17.
go back to reference Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16:269–277CrossRef Walsh JC, Mandalia S, Gazzard BG (2002) Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 16:269–277CrossRef
18.
go back to reference Easthall C, Taylor N, Bhattacharya D (2019) Barriers to medication adherence in patients prescribed medicines for the prevention of cardiovascular disease: a conceptual framework. Int J Pharm Pract 27:223–231CrossRef Easthall C, Taylor N, Bhattacharya D (2019) Barriers to medication adherence in patients prescribed medicines for the prevention of cardiovascular disease: a conceptual framework. Int J Pharm Pract 27:223–231CrossRef
19.
go back to reference Costedoat-Chalumeau N, Houssiau F, Izmirly P, Guern VL, Navarra S, Jolly M, Ruiz-Irastorza G, Baron G, Hachulla E, Agmon-Levin N, Shoenfeld Y (2019) A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther 106(2):374–382CrossRef Costedoat-Chalumeau N, Houssiau F, Izmirly P, Guern VL, Navarra S, Jolly M, Ruiz-Irastorza G, Baron G, Hachulla E, Agmon-Levin N, Shoenfeld Y (2019) A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther 106(2):374–382CrossRef
21.
go back to reference Harry O, Crosby LE, Smith AW, Favier L, Aljaberi N, Ting TV, Huggins JL, Modi AC (2019) Self-management and adherence in childhood-onset systemic lupus erythematosus: what are we missing? Lupus 28:642–650CrossRef Harry O, Crosby LE, Smith AW, Favier L, Aljaberi N, Ting TV, Huggins JL, Modi AC (2019) Self-management and adherence in childhood-onset systemic lupus erythematosus: what are we missing? Lupus 28:642–650CrossRef
22.
go back to reference Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074–1090CrossRef Farmer KC (1999) Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 21:1074–1090CrossRef
23.
go back to reference Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G (1994) Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol 34:944–949CrossRef Matsui D, Hermann C, Klein J, Berkovitch M, Olivieri N, Koren G (1994) Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol 34:944–949CrossRef
24.
go back to reference Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G (2015) Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 5:470–482CrossRef Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G (2015) Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 5:470–482CrossRef
25.
go back to reference Vik SA, Maxwell CJ, Hogan DB (2004) Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 38:303–312CrossRef Vik SA, Maxwell CJ, Hogan DB (2004) Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 38:303–312CrossRef
26.
go back to reference Daleboudt GM, Broadbent E, McQueen F, Kaptein AA (2011) Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res 63(3):342–350 Daleboudt GM, Broadbent E, McQueen F, Kaptein AA (2011) Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res 63(3):342–350
27.
go back to reference Zhang L, Luan W, Geng S, Ye S, Wang X, Qian L, Ding Y, Li T, Jiang A (2019) Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. BMC Health Serv Res 19:378CrossRef Zhang L, Luan W, Geng S, Ye S, Wang X, Qian L, Ding Y, Li T, Jiang A (2019) Lack of patient education is risk factor of disease flare in patients with systemic lupus erythematosus in China. BMC Health Serv Res 19:378CrossRef
28.
go back to reference Brown T, Twigg M, Taylor N, Easthall C, Hartt J, Budd T, Zhicheng L, Dima A, Bhattacharya D (2017) Final report for the IMAB-Q study: validation and feasibility testing of a novel questionnaire to identify barriers to medication adherence. Pharmacy Research UK, London Brown T, Twigg M, Taylor N, Easthall C, Hartt J, Budd T, Zhicheng L, Dima A, Bhattacharya D (2017) Final report for the IMAB-Q study: validation and feasibility testing of a novel questionnaire to identify barriers to medication adherence. Pharmacy Research UK, London
29.
go back to reference Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D (2002) Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheumatol 47:630–638CrossRef Mosley-Williams A, Lumley MA, Gillis M, Leisen J, Guice D (2002) Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheumatol 47:630–638CrossRef
30.
go back to reference Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, Le Guern V, Leroux G, Marra D, Morel N, Piette JC (2013) Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 27:329–340CrossRef Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, Le Guern V, Leroux G, Marra D, Morel N, Piette JC (2013) Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 27:329–340CrossRef
31.
go back to reference Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M (1991) Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 91:345–353CrossRef Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M (1991) Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 91:345–353CrossRef
32.
go back to reference Michie S, Johnston M, Francis J, Hardeman W, Eccles M (2008) From theory to intervention: mapping theoretically derived behavioural determinants to behaviour change techniques. Appl Psychol 57:660–680CrossRef Michie S, Johnston M, Francis J, Hardeman W, Eccles M (2008) From theory to intervention: mapping theoretically derived behavioural determinants to behaviour change techniques. Appl Psychol 57:660–680CrossRef
33.
go back to reference Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497CrossRef Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497CrossRef
Metadata
Title
Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population
Authors
Courtney Hardy
Dafna D. Gladman
Jiandong Su
Nathalie Rozenbojm
Murray B. Urowitz
Publication date
01-08-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 8/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-021-04898-0

Other articles of this Issue 8/2021

Rheumatology International 8/2021 Go to the issue